STAT

JUNE 11, 2023

The sudden resignation of Francis deSouza as the CEO of Illumina Sunday represents anything but an orderly transition — and it leaves a black mark on both his six-year tenure and his luckless quest to acquire the cancer diagnostics firm Grail.

109

109

Roots Analysis

SEPTEMBER 4, 2023

The need to focus on developing more efficient interventions, within stipulated timelines and budget constrains is the key driver for outsourcing operations to third-parties and the diagnostics development space is no exception.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

pharmaphorum

MAY 13, 2022

This time I’m going to focus on one company and its view on pharma’s digital commercial strategy. That pace was mirrored in the digital realm across companies, therapeutic specialities, and society at large. Dominic Tyer is a research director at DT Consulting, an Indegene company. Digital fluency and change. About the author.

Pharmaceutical Companies 127

Pharmaceutical Companies Pharmaceutical Companies Vaccines FDA 127

Roots Analysis

DECEMBER 10, 2023

Introduction In the ever-evolving landscape of medical advancements, a groundbreaking study conducted by Resonant, a Utah-based biotech company specializing in diagnostic tests for neurodegenerative diseases, is developing an Alzheimer’s blood test, a potential game-changer in the early detection of Alzheimer’s disease.

FDA 40

FDA 40

Pharmaceutical Technology

DECEMBER 7, 2022

Last week, the quest for an effective Alzheimer’s disease therapy received a notable fillip at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022, with new data on Eisai’s disease-modifying therapy lecanemab. Developing treatment biomarkers and diagnostic biomarkers may help achieve these goals.

Communication 105

Communication Immunization 105

Pharmaceutical Technology

DECEMBER 7, 2022

Last week, the quest for an effective Alzheimer’s disease therapy received a notable fillip at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022, with new data on Eisai’s disease-modifying therapy lecanemab. Developing treatment biomarkers and diagnostic biomarkers may help achieve these goals.

Communication 98

Communication Immunization 98